INDICATIONS AND USAGE
RAPAFLO, an alpha-1 adrenergic receptor antagonist, is indicated for the
treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
RAPAFLO is not indicated for the treatment of hypertension.
DOSAGE AND ADMINISTRATION
8 mg capsules taken orally once daily with a meal.
4 mg capsules taken orally once daily with a meal for those with moderate renal
impairment [Creatinine Clearance (CCr) 30-50 mL/min].
DOSAGE FORMS AND STRENGTHS
Capsules: 8 mg and 4 mg.
Renal impairment: RAPAFLO is contraindicated in patients with severe
renal impairment (Creatinine Clearance - CCr < 30 mL/min). In patients
with moderate renal impairment (CCr 30-50 mL/min), the dose should be
reduced to 4 mg once daily taken with a meal. No dosage adjustment is
needed in patients with mild renal impairment (CCr 50-80 mL/min)
Creatinine clearance can be
estimated from serum creatinine using the Cockcroft-Gault formula.
RAPAFLO is contraindicated in patients with severe renal impairment
(Creatinine Clearance - CCr < 30 mL/min).
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read